Education
About Us
Working with TipRanks
Follow Us
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
2185 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.26 - HK$2.93
Previous CloseN/A
Volume27.00K
Average Volume (3M)502.14K
Market Cap
HK$1.07B
Enterprise ValueHK$185.25M
Total Cash (Recent Filing)¥389.33M
Total Debt (Recent Filing)¥7.50M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding236,223,330
10 Day Avg. Volume795,240
30 Day Avg. Volume502,143
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H News
PremiumCompany Announcements
Shanghai Bio-Heart Launches Iberis® RDN System in Europe
PremiumCompany Announcements
Shanghai Bio-heart’s Iberis® RDN System Gains NMPA Approval
PremiumCompany Announcements
Shanghai Bio-Heart Approves Strategic Resolutions During Recent Meetings
PremiumCompany Announcements
Shanghai Bio-Heart Announces Major Transaction and Structural Amendments
PremiumCompany Announcements
Shanghai Bio-heart Schedules Shareholders’ Meeting for Governance Updates
PremiumCompany Announcements
Shanghai Bio-heart Schedules Shareholders’ Meeting for Governance Amendments
PremiumCompany Announcements
Shanghai Bio-heart Confirms Secretary Qualification Post-Waiver---
2185 FAQ
What was Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H lowest stock price was HK$1.26 and its highest was HK$2.93 in the past 12 months.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap is HK$1.07B.
When is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Mar 26, 2025 which is in 11 days.
How were Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H released its earnings results on Aug 19, 2024. The company reported -HK$0.115 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.115.
Is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H have?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 236,223,330 shares outstanding.
What happened to Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H reported an EPS of -HK$0.115 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shanghai Bio-Heart Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2185
---
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.26%
12-Months-Change
Fundamentals
Return on Equity
-14.99%
Trailing 12-Months
Asset Growth
-14.32%
Trailing 12-Months
Technical Analysis
Shanghai Fosun Pharmaceutical (Group) Co
―
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CanSino Biologics, Inc. Class H
―
---